On 22 June 2012, a case of locally acquired malaria infection was reported in Greece. The case is a 78 year old Greek citizen who presumably acquired the infection close to Marathon, Attica region.
This study found a marked reduction in vaccine serotype carriage after PCV7 implementation. The overall pneumococcal, H. influenzae and S. aureus carriage decreased slightly, but not significantly.
This study, strong of an almost complete follow-up of all children born in Denmark from 2003 to 2008, provides evidence that the DTaP-IPV-HiB vaccine is not associated to an overall increased risk of febrile seizures and epilepsy.
Despite a reduction in pertussis among younger children and infants, rates of pertussis-related sickness and death remain high compared with rates for other vaccine-preventable diseases in England and Wales.
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
Between 21 May and 5 December, 2011, 63 cases of Plasmodium vivax infection have been reported in Greece. The majority of cases (n=57) are reported from the area of Evrotas in Lakonia district, Peloponnese in southern Greece.
According to the available epidemiological and entomological information, and the arriving winter season, the intensity of malaria transmission in Evrotas, Lakonia in Greece is very low.
According to the available epidemiological and entomological information, and the arriving winter season, the intensity of malaria transmission in Evrotas, Lakonia in Greece is believed to be very low and is expected to cease shortly.